Home Other Building Blocks Tiplaxtinin

Tiplaxtinin

CAS No.:
393105-53-8
Catalog Number:
AG0038QW
Molecular Formula:
C24H16F3NO4
Molecular Weight:
439.3833
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$161
- +
10mg
98%
1 week
United States
$210
- +
50mg
98%
1 week
United States
$612
- +
100mg
98%
1 week
United States
$960
- +
Product Description
Catalog Number:
AG0038QW
Chemical Name:
Tiplaxtinin
CAS Number:
393105-53-8
Molecular Formula:
C24H16F3NO4
Molecular Weight:
439.3833
MDL Number:
MFCD09475615
IUPAC Name:
2-[1-benzyl-5-[4-(trifluoromethoxy)phenyl]indol-3-yl]-2-oxoacetic acid
InChI:
InChI=1S/C24H16F3NO4/c25-24(26,27)32-18-9-6-16(7-10-18)17-8-11-21-19(12-17)20(22(29)23(30)31)14-28(21)13-15-4-2-1-3-5-15/h1-12,14H,13H2,(H,30,31)
InChI Key:
ODXQFEWQSHNQNI-UHFFFAOYSA-N
SMILES:
OC(=O)C(=O)c1cn(c2c1cc(cc2)c1ccc(cc1)OC(F)(F)F)Cc1ccccc1
UNII:
L396QIB983
Properties
Complexity:
671  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
439.103g/mol
Formal Charge:
0
Heavy Atom Count:
32  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
439.39g/mol
Monoisotopic Mass:
439.103g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
68.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.8  
Literature
Title Journal
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity. Glia 20130501
Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives. Bioorganic & medicinal chemistry letters 20111001
Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice. Diabetes 20110701
Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity? International journal of molecular medicine 20100701
In vitro PAI-1 inhibitory activity of oxalamide derivatives. European journal of medicinal chemistry 20080401
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis. Thrombosis and haemostasis 20080401
S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thrombosis research 20080101
Tiplaxtinin impairs nutritionally induced obesity in mice. Thrombosis and haemostasis 20061201
Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arteriosclerosis, thrombosis, and vascular biology 20061001
Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1. Bioorganic & medicinal chemistry letters 20050801
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. Journal of thrombosis and haemostasis : JTH 20050601
Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. Journal of medicinal chemistry 20040701
Properties